4 Conclusion
VEGFR TKIs are promising therapeutics for multiple solid cancers.
However, all these molecular targeting agents are associated with a
variety of adverse events that can impact patients’ quality of life.
Here, we report a rare and severe case of apatinib-induced BP, which
demonstrated the effectiveness of glucocorticoid therapy for DIBP.